Ellington Management Group’s AbbVie ABBV Stock Holding History

Ellington Management Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,000	Closed	-$266K	–	512
2019 Q4	$266K	Sell	3,000 -12,000	-80%	-$996K	0.06%	347
2019 Q3	$1.14M	Sell	15,000 -100	-0.7%	-$6.86K	0.21%	97
2019 Q2	$1.1M	Buy	+15,100	New	+$1.19M	0.19%	124
2019 Q1	–	Sell	-4,800	Closed	-$443K	–	550
2018 Q4	$443K	Buy	+4,800	New	+$422K	0.13%	167
2018 Q2	–	Sell	-12,900	Closed	-$1.22M	–	471
2018 Q1	$1.22M	Buy	12,900 +1,800	+16%	+$198K	0.09%	146
2017 Q4	$1.07M	Buy	+11,100	New	+$1.05M	0.18%	78
2017 Q3	–	Sell	-5,800	Closed	-$421K	–	604
2017 Q2	$421K	Buy	5,800 +1,900	+49%	+$128K	0.06%	299
2017 Q1	$254K	Buy	+3,900	New	+$245K	0.01%	506
2016 Q4	–	Sell	-12,000	Closed	-$757K	–	521
2016 Q3	$757K	Buy	+12,000	New	+$777K	0.21%	139
2015 Q4	–	Sell	-8,535	Closed	-$464K	–	561
2015 Q3	$464K	Sell	8,535 -7,365	-46%	-$479K	0.13%	245
2015 Q2	$1.07M	Sell	15,900 -900	-5%	-$58.8K	0.26%	90
2015 Q1	$983K	Buy	+16,800	New	+$1.01M	0.2%	129

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ellington Management Group's ABBV Position: Q1 2020 in Review

Ellington Management Group sold out of AbbVie (ABBV) in Q1 2020, closing a stake of 3,000 shares — an estimated $266K sold.

Ellington Management Group first reported a position in ABBV in Q1 2015 and held it in 12 quarters. The position peaked at $1.22M in Q1 2018. 2,225 funds tracked by Wall St. Rank hold ABBV as of Q1 2020.

Ellington Management Group reported no remaining AbbVie position as of Q1 2020 after selling out during the quarter.
Ellington Management Group sold 3,000 AbbVie shares in Q1 2020, an estimated $266K.
Ellington Management Group first reported a position in AbbVie in Q1 2015 and held it in 12 quarters.
Ellington Management Group's AbbVie position peaked at $1.22M in Q1 2018.
2,225 funds tracked by Wall St. Rank held AbbVie as of Q1 2020.

Based on Ellington Management Group's 13F filing for Q1 2020, filed 15 May 2020.